Inventor
LO KIN-MING
US41 patents
⚠️ This page may combine multiple inventors who share the name “LO KIN-MING”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MERCK PATENT GMBH
15 patentsUS9676863B2Jun 13, 2017
Targeted TGFβ inhibitors
MERCK PATENT GMBH78 citations98
US7888071B2Feb 15, 2011
DNA encoding IL-2 fusion proteins with modulated selectivity
MERCK PATENT GMBH48 citations97
US7790415B2Sep 7, 2010
Enhancing the circulating half-life of antibody-based fusion proteins
MERCK PATENT GMBH43 citations96
US7670595B2Mar 2, 2010
Fc-interferon-beta fusion proteins
MERCK PATENT GMBH54 citations95
US7582288B2Sep 1, 2009
Methods of targeting multiple cytokines
MERCK PATENT GMBH14 citations93
US7767405B2Aug 3, 2010
Immunocytokine sequences and uses thereof
MERCK PATENT GMBH25 citations92
US7576193B2Aug 18, 2009
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
MERCK PATENT GMBH11 citations92
US7955590B2Jun 7, 2011
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MERCK PATENT GMBH40 citations91
US7872107B2Jan 18, 2011
Interleukin-12p40 variants with improved stability
MERCK PATENT GMBH15 citations90
US7879319B2Feb 1, 2011
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
MERCK PATENT GMBH8 citations84
US8043608B2Oct 25, 2011
Methods of using Fc-cytokine fusion proteins
MERCK PATENT GMBH13 citations83
US7459538B2Dec 2, 2008
Recombinant tumor specific antibody and use thereof
MERCK PATENT GMBH7 citations73
US11370819B2Jun 28, 2022
Targeted TGFβ inhibition
MERCK PATENT GMBH0 citations63
US7803618B2Sep 28, 2010
Recombinant tumor specific antibody and use thereof
MERCK PATENT GMBH2 citations62
US11021694B2Jun 1, 2021
SIRP-α immunoglobulin fusion proteins
MERCK PATENT GMBH2 citations61
EMD LEXIGEN RES CT CORP
10 patentsUS7148321B2Dec 12, 2006
Expression technology for proteins containing a hybrid isotype antibody moiety
EMD LEXIGEN RES CT CORP114 citations99
US6617135B1Sep 9, 2003
Multiple cytokine protein complexes
EMD LEXIGEN RES CT CORP211 citations99
US7091321B2Aug 15, 2006
Enhancing the circulating half-life of antibody-based fusion proteins
EMD LEXIGEN RES CT CORP133 citations98
US7186804B2Mar 6, 2007
IL-2 fusion proteins with modulated selectivity
EMD LEXIGEN RES CT CORP140 citations97
US6838260B2Jan 4, 2005
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
EMD LEXIGEN RES CT CORP78 citations97
US7226998B2Jun 5, 2007
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
EMD LEXIGEN RES CT CORP35 citations96
US7141651B2Nov 28, 2006
Multiple cytokine protein complexes
EMD LEXIGEN RES CT CORP50 citations96
US7067110B1Jun 27, 2006
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EMD LEXIGEN RES CT CORP110 citations96
US7169904B2Jan 30, 2007
Immunocytokine sequences and uses thereof
EMD LEXIGEN RES CT CORP46 citations95
US6969517B2Nov 29, 2005
Recombinant tumor specific antibody and use thereof
EMD LEXIGEN RES CT CORP54 citations95
FUJI IMMUNOPHARMACEUTICALS COR
3 patentsUS5726044AMar 10, 1998
Expression and export technology of proteins as immunofusins
FUJI IMMUNOPHARMACEUTICALS COR259 citations99
US5541087AJul 30, 1996
Expression and export technology of proteins as immunofusins
FUJI IMMUNOPHARMACEUTICALS COR463 citations99
US5589510ADec 31, 1996
Method for inhibiting retroviral infection by administering a naphthalenesulfonic acid compound
FUJI IMMUNOPHARMACEUTICALS COR8 citations71
GILLIES STEPHEN D
3 patentsLO KIN-MING
3 patentsUS8206718B2Jun 26, 2012
Expression and export of angiogenesis inhibitors as immunofusins
LO KIN-MING5 citations72
US8703908B2Apr 22, 2014
Expression and export of angiogenesis inhibitors as immunofusins
LO KIN-MING3 citations61
US8907066B2Dec 9, 2014
Antibody fusion proteins with a modified FcRn binding site
LO KIN-MING2 citations59